Eledon Q2 net loss $9.2M; advances tegoprubart trials across kidney, IgAN, ALS

Eledon Pharmaceuticals, Inc.

2022-Q2 EPS reported -$1.34

Net loss of $9.2M ($0.65 per share) vs $7.4M loss in Q2 2021.
Cash at $70.5M; management expects to fund operations into 2024.
FDA cleared IND for Phase 2 kidney transplant trial; first patient dosed in Phase 1b ex-US kidney study.
Positive Phase 2a ALS topline: tegoprubart met safety endpoints; showed target engagement and biomarker reduction.
Orphan Drug Designation granted for tegoprubart in islet cell transplantation; IgAN trial enrollment ongoing.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.